Use of phosphodiesterase type 5 inhibitors in assistive living and home care settings

Appl Nurs Res. 2015 Aug;28(3):251-3. doi: 10.1016/j.apnr.2015.04.006. Epub 2015 Apr 18.

Abstract

The purpose of this descriptive study was to assess frequency of phosphodiesterase type (PDE-5) inhibitor use (sildenafil, tadalafil, ardenafil) in community settings.

Methods: A retrospective record review was conducted to determine PDE-5 inhibitor use in older males (mean age 79.2) residing in three assisted living communities (n=126), or living in private homes with home care services (n=109).

Results: Two participants from assisted living had PDE-5 inhibitors listed on medication profiles, while no participants from the home care setting had any listed.

Implications: Many factors may have contributed to the absence of PDE-5 inhibitors in records, including comorbidities precluding use; fear of side effects; reluctance to report use; and lack of erectile dysfunction diagnosis to name a few. It is unknown whether sexual function, or the need for PDE-5 inhibitors was ever assessed by providers. Future research is warranted given the aging population and the benefits of holistic assessments.

Keywords: Elderly; Erectile dysfunction; Males; Phosphodiesterase inhibitors; Sexuality.

MeSH terms

  • Drug Prescriptions
  • Erectile Dysfunction / drug therapy*
  • Home Care Services*
  • Housing for the Elderly*
  • Humans
  • Male
  • Phosphodiesterase 5 Inhibitors / adverse effects
  • Phosphodiesterase 5 Inhibitors / therapeutic use*
  • Retrospective Studies
  • Sildenafil Citrate / therapeutic use
  • Tadalafil / therapeutic use

Substances

  • Phosphodiesterase 5 Inhibitors
  • Tadalafil
  • Sildenafil Citrate